Literature DB >> 3622667

Mortality related to smoking habits, respiratory symptoms and lung function.

J Olofson, B E Skoogh, B Bake, K Svärdsudd.   

Abstract

The relationship between smoking habits, respiratory symptoms and lung function at the start of the study and mortality during a follow-up period of 11 years was studied in 607 men, aged 50 and 60 years at entry and sampled from the general population. The overall mortality rate in the sample was 18%. In a logistic multiple regression model, mortality rate was significantly related to age, smoking habits, dyspnea and one of the lung function variables FEV1, VC or the slope of phase III. Smokers had a double mortality rate compared to non-smokers (22 versus 10%) after allowing for age, dyspnea and lung function. Similarly, in subjects with abnormal FEV1, VC or slope of phase III, the mortality rate was almost doubled compared to subjects with normal lung function, other factors being equal. Thus, impaired lung function is an important factor to be considered in the assessment of mortality risk, besides smoking and dyspnea.

Entities:  

Mesh:

Year:  1987        PMID: 3622667

Source DB:  PubMed          Journal:  Eur J Respir Dis        ISSN: 0106-4339


  10 in total

1.  Relation of ventilatory impairment and of chronic mucus hypersecretion to mortality from obstructive lung disease and from all causes.

Authors:  P Lange; J Nyboe; M Appleyard; G Jensen; P Schnohr
Journal:  Thorax       Date:  1990-08       Impact factor: 9.139

2.  Effects within the week on forced vital capacity are correlated with long term changes in pulmonary function: reanalysis of studies on car painters exposed to isocyanate.

Authors:  M Dahlqvist; G Tornling; N Plato; U Ulfvarson
Journal:  Occup Environ Med       Date:  1995-03       Impact factor: 4.402

3.  Nested case-control study on associations between lung function, smoking and mortality in Japanese population.

Authors:  Lizhen Hu; Michikazu Sekine; Alexandru Gaina; Hongbing Wang; Sadanobu Kagamimori
Journal:  Environ Health Prev Med       Date:  2007-11       Impact factor: 3.674

4.  Respiratory symptoms and cardiovascular causes of deaths: A population-based study with 45 years of follow-up.

Authors:  Knut Stavem; Henrik Schirmer; Amund Gulsvik
Journal:  PLoS One       Date:  2022-10-20       Impact factor: 3.752

5.  Women with lung cancer: impact on quality of life.

Authors:  L Sarna
Journal:  Qual Life Res       Date:  1993-02       Impact factor: 4.147

6.  Dyspnoea as a predictor of cause-specific heart/lung disease mortality in Bangladesh: a prospective cohort study.

Authors:  Gene R Pesola; Maria Argos; Vernon M Chinchilli; Yu Chen; Faruque Parvez; Tariqul Islam; Alauddin Ahmed; Rabiul Hasan; Muhammad Rakibuz-Zaman; Habibul Ahsan
Journal:  J Epidemiol Community Health       Date:  2016-01-14       Impact factor: 3.710

Review 7.  Dyspnea as an independent predictor of mortality.

Authors:  Gene R Pesola; Habibul Ahsan
Journal:  Clin Respir J       Date:  2014-08-20       Impact factor: 2.570

8.  Associations between lung function and future cardiovascular morbidity and overall mortality in a predominantly First Nations population: a cohort study.

Authors:  Andrew J Collaro; Anne B Chang; Julie M Marchant; Mark D Chatfield; Annette Dent; Tamara Blake; Patsi Mawn; Kwun Fong; Margaret S McElrea
Journal:  Lancet Reg Health West Pac       Date:  2021-07-05

9.  Lung function profiles and aerobic capacity of adult cigarette and hookah smokers after 12 weeks intermittent training.

Authors:  Abdessalem Koubaa; Moez Triki; Hajer Trabelsi; Liwa Masmoudi; Khaled N Zeghal; Zouhair Sahnoun; Ahmed Hakim
Journal:  Libyan J Med       Date:  2015-02-17       Impact factor: 1.743

10.  FEV1 is a better predictor of mortality than FVC: the PLATINO cohort study.

Authors:  Ana Maria B Menezes; Rogelio Pérez-Padilla; Fernando César Wehrmeister; Maria Victorina Lopez-Varela; Adriana Muiño; Gonzalo Valdivia; Carmen Lisboa; José Roberto B Jardim; Maria Montes de Oca; Carlos Talamo; Renata Bielemann; Mariana Gazzotti; Ruy Laurenti; Bartolomé Celli; Cesar G Victora
Journal:  PLoS One       Date:  2014-10-06       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.